Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has approved Valeritas' V-Go Disposable Insulin Delivery Device for use with Novo Nordisk's NovoLog for the continuous subcutaneous delivery of insulin in preset basal rates and with on-demand bolus dosing for adult patients requiring insulin.
Subscribe to our email newsletter
Valeritas has examined Humalog and NovoLog and found safe for use with the V-Go Disposable Insulin Delivery Device.
The V-Go is small, lightweight, and worn under the patients’ clothing and is not electronic while easy to operate and use.
The V-Go measures just 2.4 x 1.3 x 0.5 inches and weighs approximately 1 ounce when filled with insulin and patients apply a new V-Go to the skin daily for one 24-hour period.
Valeritas CEO Kristine Peterson said with the addition of NovoLog to the V-Go label, they have demonstrated that the two most widely prescribed fast acting insulins in the US can be used safely with the V-Go and thereby have increased healthcare professional and patient insulin options available for use with the V-Go Disposable Insulin Delivery Device.